Literature DB >> 20221762

[Histopathological diagnosis of non-alcoholic and alcoholic fatty liver disease. Grade 2 consensus-based guidelines].

A Tannapfel1, H Denk, H P Dienes, C Langner, P Schirmacher, M Trauner, B Flott-Rahmel.   

Abstract

Both alcoholic (AFL) and non-alcoholic fatty liver (NAFL) are characterized by lipid deposition in hepatocytes. The diagnosis of steatosis is made when lipid deposition exceeds 5% of hepatocytes, while involvement of more than 50% is called "fatty liver ". An additional inflammatory reaction leads to alcoholic (ASH) or non-alcoholic steatohepatitis (NASH). Steatohepatitis is present when both inflammatory infiltrates of mixed cells in the small liver lobules as well as liver cell injury in terms of ballooning can be detected.Liver biopsy represents the "gold standard" for confirming diagnosis and determining inflammatory activity and potential fibrosis of fatty liver disease.The differential diagnosis of ASH-NASH cannot be made on the basis of histological criteria alone. Steatosis, inflammatory changes and hepatocytic injury can be semiquantified as a "Brunt Score" or "NAS" (NAFLD activity score), providing the basis on which to decide whether or not steatohepatitis is present.People at increased risk of developing a fatty liver possess an increased risk of developing chemotherapy-associated steatohepatitis (CASH).Histologically, pediatric NASH differs from adult NASH and is often only clinically manifest through a mild if persistent elevation in transaminases.

Entities:  

Mesh:

Year:  2010        PMID: 20221762     DOI: 10.1007/s00292-010-1274-5

Source DB:  PubMed          Journal:  Pathologe        ISSN: 0172-8113            Impact factor:   1.011


  77 in total

1.  Relationship between aminotransferase levels and histopathological findings in patients with nonalcoholic steatohepatitis.

Authors:  A Sonsuz; M Basaranoglu; G Ozbay
Journal:  Am J Gastroenterol       Date:  2000-05       Impact factor: 10.864

2.  Chemotherapy-induced steatohepatitis in colorectal cancer patients.

Authors:  Umberto Vespasiani Gentilucci; Daniele Santini; Bruno Vincenzi; Enrica Fiori; Antonio Picardi; Giuseppe Tonini
Journal:  J Clin Oncol       Date:  2006-12-01       Impact factor: 44.544

Review 3.  Nonalcoholic steatohepatitis: pathologic features and differential diagnosis.

Authors:  Elizabeth M Brunt
Journal:  Semin Diagn Pathol       Date:  2005-11       Impact factor: 3.464

Review 4.  Pathological features of NASH.

Authors:  Elizabeth M Brunt; Dina G Tiniakos
Journal:  Front Biosci       Date:  2005-05-01

5.  Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions.

Authors:  E M Brunt; C G Janney; A M Di Bisceglie; B A Neuschwander-Tetri; B R Bacon
Journal:  Am J Gastroenterol       Date:  1999-09       Impact factor: 10.864

Review 6.  Does chemotherapy prior to liver resection increase the potential for cure in patients with metastatic colorectal cancer? A report from the European Colorectal Metastases Treatment Group.

Authors:  Bernard Nordlinger; Eric Van Cutsem; Philippe Rougier; Claus-Henning Köhne; Marc Ychou; Alberto Sobrero; Rene Adam; Dag Arvidsson; Alfredo Carrato; Vassilis Georgoulias; Felice Giuliante; Bengt Glimelius; Markus Golling; Thomas Gruenberger; Josep Tabernero; Harpreet Wasan; Graeme Poston
Journal:  Eur J Cancer       Date:  2007-09-04       Impact factor: 9.162

7.  Sinusoidal injury increases morbidity after major hepatectomy in patients with colorectal liver metastases receiving preoperative chemotherapy.

Authors:  Hiroshi Nakano; Elie Oussoultzoglou; Edoardo Rosso; Selenia Casnedi; Marie-Pierre Chenard-Neu; Patrick Dufour; Philippe Bachellier; Daniel Jaeck
Journal:  Ann Surg       Date:  2008-01       Impact factor: 12.969

8.  Concurrence of histologic features of steatohepatitis with other forms of chronic liver disease.

Authors:  Elizabeth M Brunt; Sunil Ramrakhiani; Barry G Cordes; Brent A Neuschwander-Tetri; Christine G Janney; Bruce R Bacon; Adrian M Di Bisceglie
Journal:  Mod Pathol       Date:  2003-01       Impact factor: 7.842

9.  Nonalcoholic steatohepatitis: an expanded clinical entity.

Authors:  B R Bacon; M J Farahvash; C G Janney; B A Neuschwander-Tetri
Journal:  Gastroenterology       Date:  1994-10       Impact factor: 22.682

10.  The natural history of nonalcoholic fatty liver: a follow-up study.

Authors:  M R Teli; O F James; A D Burt; M K Bennett; C P Day
Journal:  Hepatology       Date:  1995-12       Impact factor: 17.425

View more
  8 in total

1.  [Update of the S3 guidelines for pancreatic cancer. What is new for pathologists?].

Authors:  J Munding; J Lüttges; I Esposito; A Tannapfel
Journal:  Pathologe       Date:  2014-09       Impact factor: 1.011

2.  Effects of the compounds resveratrol, rutin, quercetin, and quercetin nanoemulsion on oxaliplatin-induced hepatotoxicity and neurotoxicity in mice.

Authors:  Tania E Schwingel; Caroline P Klein; Natalia F Nicoletti; Cristiana L Dora; Gabriela Hadrich; Cláudia G Bica; Tiago G Lopes; Vinicius Duval da Silva; Fernanda B Morrone
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2014-06-08       Impact factor: 3.000

3.  Ultrasound-Based Attenuation Imaging for the Non-Invasive Quantification of Liver Fat - A Pilot Study on Feasibility and Inter-Observer Variability.

Authors:  Daniel Jesper; Daniel Klett; Barbara Schellhaas; Lukas Pfeifer; Moritz Leppkes; Maximilian Waldner; Markus F Neurath; Deike Strobel
Journal:  IEEE J Transl Eng Health Med       Date:  2020-06-10       Impact factor: 3.316

4.  Laparoscopic Sleeve Gastrectomy on the Horizon as a Promising Treatment Modality for NAFLD.

Authors:  Mohamed Abdalla Salman; Ahmed Abdallah Salman; Ahmed Abdelsalam; Mohamed Atallah; Hossam El-Din Shaaban; Ahmed El-Mikkawy; Mahmoud Gouda Omar; Mai Elshenoufy
Journal:  Obes Surg       Date:  2020-01       Impact factor: 4.129

Review 5.  [Chronic liver diseases--new therapy. Are biopsies necessary?].

Authors:  A Tannapfel
Journal:  Pathologe       Date:  2013-11       Impact factor: 1.011

6.  Phosphatase and tensin homolog is a differential diagnostic marker between nonalcoholic and alcoholic fatty liver disease.

Authors:  Andrea Sanchez-Pareja; Sophie Clément; Marion Peyrou; Laurent Spahr; Francesco Negro; Laura Rubbia-Brandt; Michelangelo Foti
Journal:  World J Gastroenterol       Date:  2016-04-14       Impact factor: 5.742

7.  Establishment of a standardized liver fibrosis model with different pathological stages in rats.

Authors:  Li Li; Zongqiang Hu; Wen Li; Mingdao Hu; Jianghua Ran; Peng Chen; Qiangming Sun
Journal:  Gastroenterol Res Pract       Date:  2012-06-12       Impact factor: 2.260

8.  Age- and Gender Dependent Liver Fat Content in a Healthy Normal BMI Population as Quantified by Fat-Water Separating DIXON MR Imaging.

Authors:  Erika J Ulbrich; Michael A Fischer; Andrei Manoliu; Magda Marcon; Roger Luechinger; Daniel Nanz; Caecilia S Reiner
Journal:  PLoS One       Date:  2015-11-10       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.